Larissa Brunaldi

CAR T Cell Therapy Research Trainee @mayoclinic - Hematology, BMT and Cell Therapy.
Views are my own

[Yi Lin @YiLinMDPhD]

Truly transformative data #ASH25 Very exciting time for #mmsm patients! Understanding sequence among novel immunotherapies is more important than ever! @MayoCancerCare @IMFmyeloma #IMWG Immunotherapy Committee @SurbhiSidanaMD @DrKrinaPatel Doris Hansen @MoffittNews @HiraSMian

[British Journal of Haematology @BrJHaem]

Practical guidelines and recommendations for infection prophylaxis with CAR T and bispecific antibodies in #MultipleMyeloma from the COMMIT Consortium

https://t.co/YeaQVzLuxn

@MeeraMohanMD @End_myeloma @rajshekharucms @SusanBal9 @nsc_natalie @BerdejaJesus #mmsm

[Mehdi Hamadani, MD @MediHumdani]

Quick 2 read update on indications of CAR-T in blood disorders by @ASTCT Committee on practice guidelines. Great paper to reference in CAR manuscript introductions and to quote in painful peer-to-peer reviews #CART 🙏@abe_seb_kanate
https://t.co/IaQksOiVQQ

[Larissa Brunaldi @larissabrunaldi]

@Blood_Cancers @szusmani @MSKCancerCenter @YiLinMDPhD @MayoClinic @TischCancer @MeeraMohanMD @MedicalCollege “We saw that bispecifics work. Now let’s refine how we use them.” Nice discussion! #mmsm

[Mehdi Hamadani, MD @MediHumdani]

1/x @ASTCT Committee on Practice Guidelines releases Clinical Practice Recommendations for HCT and CAR-T in DLBCL #lymsm #bmtsm #CART
Open Access (on paywall) @ASTCT_Journal 🙏🙏🙏
https://t.co/HuU05E6lsc

[Larissa Brunaldi @larissabrunaldi]

@Blood_Cancers @Radhika_Bansl @MayoClinic Great talk from @Radhika_Bansl Studies to understand the
mechanisms of resistance of pts with BM MRD positive and PET CT positive at month 1 post CAR-T are necessary #mmsm #TCellRx @MayoCancerCare @YiLinMDPhD

[Larissa Brunaldi @larissabrunaldi]

@YiLinMDPhD @MayoCancerCare Thank you for your guidance and for inspiring me @YiLinMDPhD @Radhika_Bansl @MayoCancerCare Proud to be part of your team!

[Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 @Rfonsi1]

Ivan Borrello reviewing T cell exhaustion and CART in MM
#ASCO23RF #mmsm
⁦@IvanBorrello⁩

[Larissa Brunaldi @larissabrunaldi]

@GuiperiniMD Lucky me to be your friend @GuiperiniMD

[Mayo Clinic Comprehensive Cancer Center @MayoCancerCare]

#ASCO23 abstract1533 suggests that hospital-based outpatient setting is feasible and safe for administering and monitoring CAR-T #TCellRx and bispecific TCE therapies. #mmsm #lymsm @Radhika_Bansl @YiLinMDPhD @jonaspaludo https://t.co/2YH7atRgJT

[Radhika Bansal (She/Her) @Radhika_Bansl]

Check out abstract 1533 @ASCO #ASCO2023 for Teclistamab infusions in the outpatient setting with use of remote patient monitoring. @larissabrunaldi @YiLinMDPhD @jonaspaludo

👉23pt =155 infusions = 98% administered outpt (80% NEVER ADMITTED) ##HCSM #MedEd #mmsm #DigitalHealth

[Yi Lin @YiLinMDPhD]

@larissabrunaldi presented @MayoCancerCare experience with outpatient management of #CART & #BsAb Teclistamab: 23 patient and 155 injections given. #ASCO23

[Yi Lin @YiLinMDPhD]

WoMMen in #mmsm

[Yi Lin @YiLinMDPhD]

Check out poster by @larissabrunaldi, visiting researcher from Brazil, presents data from @MayoCancerCare study of 161 myeloma pts treated with #CART that bone marrow and PET MRD negativity is prognostic for early relapse vs prolonged PFS #mmsm #ASCO23

[Yi Lin @YiLinMDPhD]

@Rfonsi1 Thanks for the shout-out, Dr. Fonseca! Would be great if ASCO and other meetings with large international participation would allow interpreters for more engaged Q&A. It’s another aspect of DEI for our scientific community.

[Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 @Rfonsi1]

I heard yesterday that a presenter from China at #ASCO23 was struggling to answer questions due to language barriers, after she did an excellent presentation. Dr. @YiLinMDPhD stepped in and said: “I’m here to translate.” Well done!

[Vincent Rajkumar @VincentRK]

For #ASCO23

How I treat myeloma: a few slides.

[Elizabeth A. Mittendorf, MD, PhD, MHCM, FASCO @ASCOPres]

My theme, “Partnering w patients, the cornerstone of clinical care and research” builds on my career of more than 30 yrs & resonates w many of the challenges in oncology today. The theme promotes the preeminence of the relationship btwn pts & the oncology clinician #ASCO23

[Larissa Brunaldi @larissabrunaldi]

🤔@Radhika_Bansl What about extra medullary disease? Is there a role from PET-CT in this scenario? #ASCO2023

[Larissa Brunaldi @larissabrunaldi]

👉BM MRD at month one post #CART is prognostic regardless bone marrow cellularity for pts with MM https://t.co/ySaskSMPLB #mmsm @BloodCancerJnl
@Radhika_Bansl @YiLinMDPhD @Taxkourel @Rfonsi1 @myelomaMD